Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is presented as the stronger 2026 healthcare investment after FY2025 revenue rose 9.9% to nearly $36.7B, net income reached about $7.7B, and free cash flow totaled roughly $8.1B. The company has a 21% net margin and raised its full-year outlook, although its 6.3x debt-to-equity ratio, distributor concentration, biosimilar exposure, and drug-pricing risks remain notable. Moderna's FY2025 revenue fell 39.2% to about $1.9B and it posted a $2.8B net loss with negative $2.1B free cash flow, leaving its upside dependent on pipeline execution despite positive FDA advisory support for its mRNA flu vaccine.

Analysis

The more investable expression is not simply AMGN long/MRNA short; it is mature commercial execution versus binary platform optionality. AMGN’s key equity risk is that biosimilar and IRA-related price erosion arrives while leverage constrains buybacks or acquisition capacity, making its valuation vulnerable to a lower-growth pharmaceutical multiple. Conversely, MRNA’s low financial leverage is less important than its cash-burn trajectory: the stock will trade on evidence that non-COVID products can reduce the revenue gap before the market begins pricing future dilution.

AMGN’s distributor concentration creates an underappreciated working-capital and gross-to-net risk. MCK, COR, and CAH have bargaining power over inventory timing, formulary access, and channel terms; even without lost prescriptions, distributor destocking or tougher rebates could make reported quarterly growth materially noisier. The distributors are not clean beneficiaries, however, because drug-price controls and biosimilar substitution can compress absolute dollar economics across the specialty channel.

Over the next 1-3 months, MRNA is likely more sensitive to vaccine-order visibility, updated respiratory-vaccine guidance, and any clinical readout than to conventional valuation arguments. A positive regulatory signal can generate sharp upside from a depressed base, but durable rerating requires management to demonstrate lower cash burn and credible launch uptake. Over 6-18 months, AMGN’s relative outcome hinges on whether growth brands offset legacy franchise erosion without further balance-sheet stress; MRNA’s hinges on converting its pipeline from scientific optionality into recurring commercial revenue.

Consensus appears too comfortable treating AMGN as defensive and MRNA as purely speculative. AMGN’s defensiveness weakens if reimbursement changes hit multiple established franchises simultaneously, while MRNA’s downside may be more bounded than assumed if its liquidity runway remains intact and one respiratory or oncology program validates platform economics. The proper catalyst test is operational: AMGN must sustain organic growth and cash conversion after price/mix effects, while MRNA must show sequential improvement in non-pandemic revenue and annualized operating cash burn.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long AMGN / short MRNA in dollar-neutral sizing. Target 10-15% relative outperformance; stop if MRNA reports a material non-COVID commercial inflection or pivotal clinical success, or if AMGN cuts guidance/FCF expectations.
• For long-only healthcare exposure, accumulate AMGN only on post-earnings weakness rather than chase a quality narrative. Require confirmation that gross-to-net pressure and biosimilar losses are contained; reassess if net debt/EBITDA rises or management relies on incremental leverage to support capital returns.
• Treat MRNA as an event-driven watch item, not a core short. Consider defined-risk put spreads only ahead of earnings or vaccine-demand updates if cash-burn guidance remains elevated; avoid naked short exposure because regulatory or oncology-data upside can reprice the stock abruptly.
• Monitor MCK, COR, and CAH for inventory, rebate, and specialty-distribution commentary during their next reports. A coordinated signal of tougher manufacturer terms or lower branded-drug volume would be an early warning for AMGN revenue quality, while stable channel commentary would remove a near-term bear case.